Roche Holding’s fair value estimate has edged up to about CHF 312 from roughly CHF 305, supported by a slightly higher long ...

Fewer patients with hypereosinophilic syndrome receiving benralizumab plus background therapy vs. placebo had flares, ...

As of Thursday, December 04, Kyverna Therapeutics, Inc.’s KYTX share price has surged by 5.98%, which has investors ...

As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, ...

Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell ...

Detailed price information for Artiva Biotherapeutics Inc (ARTV-Q) from The Globe and Mail including charting and trades.

All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up ...

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient ...

When people ask their doctors about lupus causes, their answer can sometimes sound frustratingly vague. While they know that ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported third-quarter results and outlined major clinical and regulatory milestones that position its lead therapy, rese-cel, as a potential ...

An analysis of kidney biopsies before and after obinutuzumab treatment of lupus nephritis showed histologic remission or near remission in a greater proportion of patients than had complete renal ...